(NasdaqGM:STIM), Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024 Generated Greenbrook clinic revenue of $21.8 million in Q3 2025, an increase of 25% on an adjusted pro forma basis versus Q3 2024 Continued cash management improvement, with cash used in operations of $0.8 million in […]
(NASDAQ:CELC), MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Stifel 2025 Healthcare Conference to be held in New York on November 11-13, 2025. Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, is scheduled for
— AmacaThera receives US$5 million upfront and up to US$225 million in potential future milestone payments with Pacira BioSciences for AMT-143, AmacaThera's long-acting non-opioid anestheticfor post-operative pain — AMT-143 leverages AmacaThera's breakthrough tunable hydrogel platform, delivering sustained local release of ropivacaine — AmacaThera and Pacira will collaborate on the Phase 2 clinical program, and Pacira
2025 Canadian Poverty and Socioeconomic Analysis reveals growing anxiety over finances, jobs and essential needs A new national report from The Salvation Army shows that a growing number of Canadians are struggling to stay afloat, with fewer people confident in their financial future and increasing reliance on essential support services. The Salvation Army surveyed more
LakeShore Biopharma Co., Ltd (“LakeShore Biopharma” or the “Company”) (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Oceanpine Skyline
Ocular Therapeutix(TM) Reports Third Quarter 2025 Financial Results and Business Highlights GlobeNewswire November 04, 2025 Recent Investor Day highlighted how AXPAXLI(TM) is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability Announced today that SOL-R achieved target randomization of 555 subjects Exceptional execution and retention in AXPAXLI wet AMD registrational
Prelude Therapeutics Announces Strategic Business Update GlobeNewswire November 04, 2025 Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement with Incyte, as previously announced, includes upfront payment of $35 million, a $25 million equity investment and $100
Xometry Reports Record Third Quarter 2025 Results GlobeNewswire November 04, 2025 Q3 revenue increased 28% year-over-year to a record $181 million, driven by robust marketplace growth. Q3 marketplace revenue growth accelerated to 31% year-over-year, driven by strong enterprise growth and expanded networks of buyers and suppliers. Q3 gross profit increased 29% year-over-year to a record
Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference GlobeNewswire November 04, 2025 MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Stifel 2025 Healthcare Conference to be held in New York on November 11-13, 2025.
Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan GlobeNewswire November 04, 2025 Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024 Generated Greenbrook clinic revenue of $21.8 million in Q3 2025, an increase of 25% on an adjusted pro forma